General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Clinical trials

Clinical trials

Clinical trials are research studies intended to answer scientific questions and find better ways to treat or prevent diseases. They are fundamental to the development of innovative medicines and vaccines that treat and prevent illness.

Clinical studies are conducted to determine whether a new treatment is both safe and effective. Such studies are possible because volunteers (healthy volunteers and patients) agree to participate and try new medicines or vaccines.

Drugs tested in clinical trials can be:

  • Drugs that have not yet been approved by health authorities
  • Drugs that are currently available for sale, and are being tested to improve existing formulations or evaluate the potential of the drug to treat other diseases.

To learn more about the various phases of clinical trials, visit:

Participating in a Novartis clinical trial

The success of clinical trials depends on the participation of volunteers. Participants in clinical trials gain access to new research treatments not yet widely available while helping others by contributing to medical research.

Novartis makes a conscientious effort to ensure that patients and healthcare providers are informed about ongoing clinical trials by posting trial information on publicly accessible websites.

Novartis is currently conducting clinical trials worldwide for a number of diseases. For more information about ongoing interventional Novartis-sponsored clinical trials, visit:

Completed Novartis clinical trials

Novartis recognizes the importance of informing the public about the results of its interventional clinical trials, regardless of the outcome. In alignment with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the World Health Organization (WHO), Novartis has taken several important steps to ensure that information about clinical trial results reach the public in a timely and balanced manner.

We make the results of our clinical trials publicly available through peer-reviewed publications and posting of results in the Novartis clinical trial results database and/or at Knowing the results of these trials enables both patients and their healthcare providers to make well-informed decisions regarding treatment risks and benefits.

To learn more about how Novartis is leading in clinical trial data transparency, review:

To learn more about the results of Novartis-conducted trials, visit: